PMID- 30694451
OWN - NLM
STAT- MEDLINE
DCOM- 20190417
LR  - 20200225
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Linking)
VI  - 109
IP  - 4
DP  - 2019 Apr
TI  - Prophylaxis and treatment with mycophenolate mofetil in children with 
      graft-versus-host disease undergoing allogeneic hematopoietic stem cell 
      transplantation: a nationwide survey in Japan.
PG  - 491-498
LID - 10.1007/s12185-019-02601-5 [doi]
AB  - We investigated the safety and efficacy of mycophenolate mofetil (MMF) in the 
      prevention and treatment of graft-versus-host disease (GVHD) using a nationwide 
      retrospective survey in Japanese children undergoing hematopoietic stem cell 
      transplantation (HSCT). Overall, 141 children undergoing allogeneic HSCT for 
      hematological malignancy (n = 84), non-malignancy (n = 52), and solid tumors 
      (n = 5) were administered MMF orally (median 8 years; range 0-15 years; 89 males 
      and 52 females) during 1995-2011. Donors were primarily unrelated and mismatched 
      related. In the GVHD prophylaxis group, 29% and 8.6% of patients developed grade 
      II-IV and III-IV GVHD, respectively. Of the 32 evaluable patients, 16% developed 
      chronic [limited (n = 4) and extensive (n = 1)] GVHD. In the acute GVHD treatment 
      group, 61% had decreased grade. In the chronic GVHD treatment group, 36% had 
      improved symptoms. Combined immunosuppressant was reduced or discontinued in 61% 
      patients. Major adverse events (AEs) were neutropenia (4.3%), infection (3.5%), 
      thrombocytopenia (2.1%), myelosuppression (2.1%), and diarrhea (1.4%). MMF dosage 
      was reduced in two children due to grade >/= 3 AEs; two children died from 
      infection. MMF thus may be well tolerated in children, and may be an effective 
      option for prophylaxis and treatment of acute and chronic GVHD.
FAU - Kawashima, Nozomu
AU  - Kawashima N
AUID- ORCID: 0000-0001-5700-4481
AD  - Department of Hematology and Oncology, Children's Medical Center, Japanese Red 
      Cross Nagoya First Hospital, 3-35 Michishita-cho, Nakamura-ku, Nagoya, 453-8511, 
      Japan. kwnozomu@med.nagoya-u.ac.jp.
AD  - Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 
      Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan. kwnozomu@med.nagoya-u.ac.jp.
FAU - Iida, Minako
AU  - Iida M
AD  - Department of Promotion for Blood and Marrow Transplantation, Aichi Medical 
      University School of Medicine, Nagakute, Japan.
FAU - Suzuki, Ritsuro
AU  - Suzuki R
AD  - Department of Oncology and Hematology, Shimane University Hospital Innovative 
      Cancer Center, Izumo, Japan.
FAU - Fukuda, Takahiro
AU  - Fukuda T
AD  - Department of Hematopoietic Stem Cell Transplantation, National Cancer Center 
      Hospital, Tokyo, Japan.
FAU - Atsuta, Yoshiko
AU  - Atsuta Y
AD  - Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
FAU - Hashii, Yoshiko
AU  - Hashii Y
AD  - Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, 
      Japan.
FAU - Inoue, Masami
AU  - Inoue M
AD  - Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Izumi, 
      Japan.
FAU - Kobayashi, Masao
AU  - Kobayashi M
AD  - Department of Pediatrics, Hiroshima University Graduate School of Biomedical & 
      Health Sciences, Hiroshima, Japan.
FAU - Yabe, Hiromasa
AU  - Yabe H
AD  - Department of Cell Transplantation and Regenerative Medicine, Tokai University 
      School of Medicine, Isehara, Japan.
FAU - Okada, Keiko
AU  - Okada K
AD  - Department of Pediatric Hematology/Oncology, Osaka City General Hospital, Osaka, 
      Japan.
FAU - Adachi, Souichi
AU  - Adachi S
AD  - Department of Human Health Sciences, Graduate School of Medicine, Kyoto 
      University, Kyoto, Japan.
FAU - Yuza, Yuki
AU  - Yuza Y
AD  - Department of Hematology and Oncology, Tokyo Metropolitan Children's Medical 
      Center, Fuchu, Japan.
FAU - Kawa, Keisei
AU  - Kawa K
AD  - Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Izumi, 
      Japan.
FAU - Kato, Koji
AU  - Kato K
AD  - Department of Hematology and Oncology, Children's Medical Center, Japanese Red 
      Cross Nagoya First Hospital, 3-35 Michishita-cho, Nakamura-ku, Nagoya, 453-8511, 
      Japan.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
DEP - 20190129
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - HU9DX48N0T (Mycophenolic Acid)
SB  - IM
MH  - Adolescent
MH  - Allografts
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Graft vs Host Disease/*prevention & control
MH  - Hematologic Neoplasms/*therapy
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Japan
MH  - Male
MH  - Mycophenolic Acid/*administration & dosage/adverse effects
MH  - *Registries
OTO - NOTNLM
OT  - Graft-versus-host disease
OT  - Mycophenolate mofetil
OT  - Pediatric
OT  - Prophylaxis
OT  - Treatment
EDAT- 2019/01/30 06:00
MHDA- 2019/04/18 06:00
CRDT- 2019/01/30 06:00
PHST- 2018/11/29 00:00 [received]
PHST- 2019/01/17 00:00 [accepted]
PHST- 2019/01/16 00:00 [revised]
PHST- 2019/01/30 06:00 [pubmed]
PHST- 2019/04/18 06:00 [medline]
PHST- 2019/01/30 06:00 [entrez]
AID - 10.1007/s12185-019-02601-5 [pii]
AID - 10.1007/s12185-019-02601-5 [doi]
PST - ppublish
SO  - Int J Hematol. 2019 Apr;109(4):491-498. doi: 10.1007/s12185-019-02601-5. Epub 
      2019 Jan 29.